Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders

Eugene R. Schiff, Jules L. Dienstag, Selim Karayalcin, Ian S. Grimm, Robert P. Perrillo, Petr Husa, R. A. De Man, Zachary Goodman, Lynn D. Condreay, Lynn M. Crowther, Mary A. Woessner, Penny J. McPhillips, Nathaniel A. Brown

Research output: Contribution to journalArticlepeer-review

122 Scopus citations

Abstract

Background/Aims: Lamivudine is effective in treatment-naive patients with chronic hepatitis B, but its role in interferon nonresponders has not been described. We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously. Methods: Patients were randomized to lamivudine (100 mg) or placebo for 52 weeks or to a 24-week regimen of lamivudine plus interferon. Primary treatment comparisons were at week 52, with a 16-week posttreatment follow-up period. Measurements included histology (primary endpoint), HBeAg response, normalization of alanine aminotransferase, reduction of hepatitis B virus (HBV) DNA, and safety. Results: Among 238 patients, histologic response was significantly more common in patients treated with lamivudine (52 versus placebo 25%, P = 0.002) or the combination regimen (32%, P = 0.01). HBeAg loss was also more common with lamivudine (33 versus 13 versus 21%), as were virologic and alanine aminotransferase responses. Among 28 subjects with HBeAg loss/seroconversion, 71% had durable responses 16 weeks posttreatment. Conclusions: Lamivudine for 52 weeks is as effective in interferon nonresponders as in previously reported treatment-naive patients; however, a combination of lamivudine for 24 weeks and interferon for 16 weeks was not effective in this population.

Original languageEnglish (US)
Pages (from-to)818-826
Number of pages9
JournalJournal of Hepatology
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2003

Keywords

  • Chronic hepatitis
  • Hepatitis B
  • Hepatitis B e antigen
  • Interferon
  • Interferon nonresponder
  • Lamivudine

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders'. Together they form a unique fingerprint.

Cite this